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BACKGROUND. Tranilast is a therapeutic agent used in treatment of allergic diseases,
although it has been reported to show anti-tumor effects on some cancer cells. To elucidate the
effects of tranilast on prostate cancer, we investigated the mechanisms of its anti-tumor effect on
prostate cancer.
METHODS. The anti-tumor effects and related mechanisms of tranilast were investigated both
in vitro on prostate cancer cell lines and bone-derived stromal cells, and in vivo on severe
combined immunodeficient (SCID) mice. We verified its clinical effect in patients with
advanced hormone refractory prostate cancer (HRPC).
RESULTS. Tranilast inhibited the proliferation of LNCaP, LNCaP-SF, and PC-3 cells in a dose-
dependent manner and growth of the tumor formed by inoculation of LNCaP-SF in the dorsal
subcutis and in the tibia of castrated SCID mice. Flow cytometry and TUNEL assay revealed
induction of cell cycle arrest and apoptosis by tranilast. Tranilast increased expression of
proteins involved in induction of cell cycle arrest and apoptosis. Coculture with bone-derived
stromal cells induced proliferation of LNCaP-SF cells. Tranilast also suppressed secretion of
transforming growth factor b1 (TGF-b1) from bone-derived stromal cells, which induced their
differentiation. Moreover, tranilast inhibited TGF-b1-mediated differentiation of bone-derived
stromal cells and LNCaP-SF cell migration induced by osteopontin. In the clinical investigation,
PSA progression was inhibited in 4 of 16 patients with advanced HRPC.
CONCLUSIONS. These observations suggest that tranilast may be a useful therapeutic agent
for treatment of HRPC via the direct inhibitory effect on cancer cells and suppression of TGF-b1-
associated osteoblastic changes in bone metastasis. Prostate 69: 1222–1234, 2009.
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INTRODUCTION
Prostate cancer is the most frequently diagnosed
cancer and the second leading cause of cancer-related
death in the USA [1]. Skeletal metastases occur in
approximately 80% of patients with advanced prostate
cancer, and no curative therapies are available for
advanced prostate cancer [2,3]. Although hormone
therapy is useful, its effects are limited because prostate
cancer changes to an androgen-independent pheno-
type over several years of therapy [4,5]. It is extremely
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difficult to cure hormone refractory prostate cancer
(HRPC) with no clear consensus about the appropriate
management strategy. Recently, some oral salvage
therapies, such as alternative anti-androgens, estra-
mustine phosphate (EMP), and dexamethasone (DEX)
for HRPC have been reported [6–8]. However, as their
effects do not last for a long time, new agents are
required for the treatment of advanced HRPC.
Bone is constantly being remodeled and releases
potential chemoattractants for tumor cells [9]. The
growth rate of prostate cancer cells accelerates once
they enter the bone environment, suggesting that
factors are present in bone that stimulate tumor
proliferation [10]. In the bone marrow, several growth
factors and cytokines are produced by osteoblasts and
are incorporated into the bone matrix [11]. Trans-
forming growth factor b (TGF-b) is known to play an
extremely important role in the local modulation of
bone metabolism [12]. TGF-b1 is released by osteoblasts
and bone stromal cells and is a potent paracrine
stimulator of prostate cancer growth in bone meta-
stasis. Bone-derived TGF-b1 forms a vicious cycle to
promote the development and progression of bone
metastasis. In early tumorigenesis, TGF-b is a tumor
suppressor, but advanced cancers lose their growth
inhibition and are often stimulated to metastasize by
TGF-b [13]. Yonou et al. [14] demonstrated that the
serine protease activity of prostate-specific antigen
(PSA) stimulated osteoblast proliferation, differentia-
tion, and secretion of TGF-b from osteoblasts, and
simultaneously decreased the number of osteoclasts.
We encountered a case in which progression of
serum PSA of the HRPC patient was prevented for a
long time with the use of tranilast for allergic rhinitis.
Tranilast was originally developed as an anti-allergic
drug for systemic or topical treatment of bronchial
asthma, atopic dermatitis, and allergic conjunctivitis.
Its usefulness in such applications is derived from
its pharmacological ability to inhibit the release of
chemical mediators from mast cells and to conse-
quently suppress hypersensitivity reaction. Tranilast
was also found to inhibit TGF-b production from
human monocytes and macrophages, TGF-b expres-
sion in rat stellate cells, and TGF-b-induced collagen
synthesis by keloid fibroblasts [15]. Furthermore,
tranilast has been shown to have only minor clinical
toxicity, such as cystitis and hepatitis, and no serious
toxicity such as myelosuppression. Recently, several
investigators reported anti-tumor effects of tranilast
through different mechanisms. Shime et al. [16]
reported that tranilast inhibited the proliferation of
uterine leiomyoma cells in vitro through G1 arrest
associated with the induction of p21 and p53. Nie et al.
[17] reported that tranilast inhibited the insulin-like
growth factor-1 (IGF-1)-induced cell growth in MCF-1
breast cancer cells by blocking calcium entry. Tranilast
also inhibited cancer cell growth by suppressing
intercellular interaction between cancer cells and
stromal fibroblast in OCUM-2M gastric cancer cells
and OSC-19 oral cancer cells [18,19]. However, there
have been no reports about anti-tumor effects of
tranilast on prostate cancer cells or clinical reports
on any cancer cells. Therefore, anti-tumor effects of
tranilast on prostate cancer cells should also be
examined in both basic and clinical studies.
Based on these observations, we hypothesized that
tranilast may cause apoptosis and cell cycle arrest of
prostate cancer cells and inhibit production of TGF-b1
by osteoblasts and bone stromal cells, such as fibro-
blasts, in bone metastases. In the present study, we
confirmed the effects of tranilast on prostate cancer
cells and on inhibition of TGF-b1 production from bone
stromal cells. In addition, we evaluated the effective-





acid) was obtained from Kissei Pharmaceutical Co.,
Ltd. (Matsumoto, Japan). Tranilast was dissolved in
dimethyl sulfoxide (DMSO; Sigma–Aldrich, St. Louis,
MO) for the in vitro studies and in 0.5% carboxymethyl
cellulose sodium salt (CMC; Wako, Osaka, Japan)
solution for the in vivo studies.
Cell Line andCulture
Human SaOS-2 osteosarcoma cells (European Col-
lection of Cell Cultures, Salisbury, UK) and PC-3 cells
(American Type Culture Collection, Manassas, VA)
were cultured in RPMI supplemented with 1% pen-
icillin/streptomycin (Invitrogen, Carlsbad, CA) and
5% fetal bovine serum (FBS; Sigma–Aldrich). LNCaP
parental cells (American Type Culture Collection) were
cultured in DMEM supplemented with 1% penicillin/
streptomycin and 5% FBS. An androgen-independent
LNCaP cell line (LNCaP-SF), which was established
in our laboratory after long-term subculture of the
parental LNCaP cells in DMEM and 5% charcoal-
stripped FBS (CCS; Hyclone, Logan, UT), was also used
[20]. Bone-derived stromal cells 1 (BDSC-1) were
obtained from the 11th rib of a 48-year-old Japanese
man during left adrenalectomy for pheochromocy-
toma. Bone-derived stromal cells 2 (BDSC-2) were
obtained from the 11th rib of a 58-year-old Japanese
man during left nephroureterectomy for ureteral
cancer without metastasis. Bone metastasis stromal
cells (BmetSC) were obtained from the left thigh bone of
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a 66-year-old Japanese man during palliative curettage
for the pain of metastatic prostate cancer. We obtained
informed consent for use of all specimens for experi-
ments before each operation. These bone samples were
scraped into bone chips and further processed with
a bone grinder. Bone chips were cultured in RPMI
supplemented with 1% penicillin/streptomycin and
10% FBS [21]. Normal human prostate stromal cells
(PrSC; Cambrex, East Rutherford, NJ) were cultured
using SCGM Bullet Kit (Cambrex). Each cell line was
maintained at 378C in a humidified atmosphere with
5% CO2.
Animal Study
Severe combined immunodeficient (SCID) mice
were castrated 1 week before implantation of LNCaP-
SF cells. LNCaP-SF cells were combined with 50%
Matrigel (Collaborative Biomedical Products, Bedford,
MA) and 1 106 or 5 105 cells were prepared for
injection into the dorsal subcutis or the left tibia of
anesthetized (pentobarbital at 50 mg/kg body weight
i.p.) 5-week-old castrated male SCID mice, respec-
tively. Intratibial injection was performed using a
29-gauge, 0.5-in. needle inserted through the tibial
plateau of the flexed knee as described previously [22].
Four weeks after inoculation, the dorsal tumor volume
reached 142 134 mm3, and mice were divided into
three groups so that mean volume of each group
became the same. The mice were then treated orally for
14 days with vehicle (control) or 100 or 200 mg/kg/day
of tranilast in 5% CMC. Body weight was monitored
at weekly intervals. Mice injected subcutaneously with
LNCaP-SF cells were sacrificed 14 days following the
start of oral administration of tranilast or vehicle alone.
The tumor volume (V) was calculated from the length
(l) and width (w) according to the formula V¼ lw2/2.
For mice receiving intratibial injections, 300 mg/kg/
day of tranilast in 5% CMC solution or 5% CMC
solution as a control was administered orally for
14 days from 12 weeks after injection. Mice injected
into the left tibia were sacrificed at 14 weeks following
intratibial injection. This protocol was approved by
the Institutional Animal Care and Use Committee of
the Graduate School of Medical Science, Kanazawa
University.
Cell Proliferation
PC-3 and SaOS-2 cells were plated at a density of
5 104 cells onto six-well plates with RPMI 5% CCS and
LNCaP, and LNCaP-SF cells were plated at a density of
1 105 cells onto six-well plates with DMEM 5% CCS.
They were allowed to adhere and proliferate for 24 hr.
Subsequently, each cell line was starved with serum-
free medium (RPMI or DMEM) in the TGF-b1 experi-
ment. Cells were incubated with fresh medium
containing various doses between 0 and 300 mmol/L
of tranilast for 24, 48, and 72 hr in the tranilast
experiment, or 0, 0.5, and 5 ng/mL of human TGF-b1
(R&D Systems, Minneapolis, MN) daily for 7 days for
the TGF-b1 experiment. In each experiment, cells were
harvested and cell number was counted in triplicate
using a hemocytometer.
ReverseTranscription-PCR
Twenty-four hours after seeding of each prostate
cancer cell line at 5 105 cells per 6-cm dish, tranilast
was added (0–300 mmol/L) for 48 hr, and cells were
harvested. Total RNA extraction from cell cultures was
performed using an RNeasy Mini Kit (Qiagen, Hilden,
Germany). Total RNA (1 mg) was subjected to reverse
transcription using ThermoScript RT (Invitrogen).
Reverse transcription-PCR (RT-PCR) was performed
using TaKaRa Ex Taq Hot Start Version (Takara Bio,
Shiga, Japan). The sense and anti-sense primers used
and RT-PCR conditions are shown in Table I.
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TABLE I. The PrimersUsed for RT-PCRAnalysis
Gene Sequence and annealing temp. (8C) Cycles
GAPDH Forward 50-GAC CAC AGT CCA TGC CAT CA-30 60 21
Reverse 50-TCC ACC ACC CTG TTG CTG TA-30
p53 Forward 50-TCC TCT TGC AGC AGC CAG ACT GCC T-30 65 28
Reverse 50-GGG CAA CTG ACC GTG CAA GTC ACA G-30
p21 Forward 50-AGG AGG CCC GTG AGC GAT GGA ACT T-30 65 28
Reverse 50-CTG TCA TGC TGG TCT GCC GCC GTT T-30
p27 Forward 50-CTA GAG GGC AAG TAC GAG TGG CAA G-30 65 32
Reverse 50-GAA GAA TCG TCG GTT GCA GGT CGC T-30
Osteopontin Forward 50-TAT GAT GGC CGA GGT GAT AGT GTG G-30 65 30
Reverse 50-TAA TCT GGA CTG CTT GTG GCT GTG G-30
cbfa-1 Forward 50-CCC ACG AAT GCA CTA TCC AGC CAC C-30 65 30
Reverse 50-ATT CGA GGT GGT GGT GCA TGG CGG A-30
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Western BlottingAnalysis
Twenty-four hours after each prostate cancer cell
line was seeded at 1 106 cells per 6-cm dish, tranilast
was added (0–300 mmol/L) for 48 hr. Cells were
harvested, washed with PBS, and lysed using radio-
immunoprecipitation assay buffer (50 mmol/L Tris–
HCl, pH 8.0, 150 mmol/L NaCl, 0.1% Triton X-100,
0.01 mg/mL aprotinin, 0.05 mg/mL phenylmethylsul-
fonyl fluoride). The nuclei and cellular debris were
removed by centrifugation at 12,000g for 10 min at 48C.
Protein was quantified according to the method of
Bradford, and equal amounts of protein were loaded
and electrophoresed on a 10% or 12.5% sodium dodecyl
sulfate–polyacrylamide gel. Proteins in the gel were
transferred onto polyvinylidene difluoride membranes
(Bio-Rad, Hercules, CA) and pre-blocked with casein
PBS and 0.05% Tween-20 for 1 hr at room temperature.
Membranes were incubated with mouse monoclonal
antibody against p53, p27, and full-length poly (ADP-
ribose) polymerase (PARP), and rabbit polyclonal
antibody against p21, Fas (Santa Cruz Biotechnology,
Santa Cruz, CA), and cleaved PARP (Abcom,
Cambridge, MA). Horseradish peroxidase-conjugated
secondary antibody against anti-mouse monoclonal or
anti-rabbit monoclonal or polyclonal antibody was
used and protein bands were visualized with enhanced
chemiluminescence reagent (SuperSignal West Pico
Chemiluminescent Substrate; Pierce, Rockford, IL).
Equal loading of proteins was confirmed using
Ponceau S solution (Sigma–Aldrich).
Cell Cycle Analysis
Twenty-four hours after each prostate cancer cell
line was seeded at 1 106 cells per 6-cm dish, tranilast
was added (0–300 mmol/L) for 48 hr. Cells were then
harvested, washed with PBS, and fixed in 100% ethanol
for 30 min at 208C. They were then treated with 5 mg/
mL of RNase for 30 min, stained with 50 mg/mL
propidium iodide, and analyzed by flow cytometry
for cell cycle status (Beckman–Coulter, Fullerton,
CA).
Apoptosis Assay
Twenty-four hours after each prostate cancer cell
line was seeded at 5 104 cells per six-well plate,
tranilast was added (0 or 300 mmol/L) for 48 hr. The
terminal deoxynucleotidyl transferase-mediated
dUTP-biotin nick end-labeling (TUNEL) technique
was used to detect apoptotic cells using an in situ
Apoptosis Detection Kit (Takara Bio) in accordance
with the manufacturer’s instructions. Optical micro-
scopy was performed to confirm the existence of
positively stained cells.
Coculture of SaOS-2 or Bone-Derived Stromal
CellsWith LNCaP-SF
Aliquots of 5 104 SaOS-2, BDSC-1, BDSC-2, or
BmetSC cells were plated onto Cell Culture Inserts
(1.0 mm pore size 12-well format; Becton–Dickinson,
Franklin Lakes, NJ) with RPMI 10% FBS in 12-well
plates containing RPMI 10% FBS for 24 hr. Each cell line
was starved with serum-free DMEM and applied to
12-well plates containing cultures of LNCaP-SF cells as
follows. LNCaP-SF cells were plated at a density of
5 104 cells onto 12-well plates with DMEM 5% CCS.
After cells were allowed to adhere and proliferate for
24 hr, they were starved with serum-free DMEM. Then,
each Cell Culture Insert including BDSC or SaOS-2 was
placed on these 12-well plates. After 7 days, LNCaP-SF
cells were harvested and cell number was counted in
triplicate using a hemocytometer.
Morphological Transformation of Bone-Derived
Stromal Cells byTGF-b1
After aliquots of 5 104 BDSC-1, BDSC-2, or BmetSC
cells were plated onto 12-well plates with RPMI 10%
FBS, they were allowed to adhere and proliferate for
24 hr. Subsequently, each cell line was starved with
serum-free RPMI. Cells were incubated with fresh
medium containing various doses between 0, 0.5, and
5 ng/mL TGF-b1 and 0.5 ng/mL TGF-b1 with 10 mg/
mL of pan-specific TGF-b antibody (R&D Systems)
daily or 0.5 ng/mL of TGF-b1 daily with 0–300 mmol/L
of tranilast every other day for 10 days. In each
experiment, cells were observed morphologically and
the cellular area of each of 20 cells was determined
using NIH image1 to express the changes as objective
values. Cells were subsequently harvested and cell
number was counted in triplicate using a hemocyto-
meter. Total RNA extraction and RT-PCR were
performed as described above.
Enzyme-Linked Immunoassay (ELISA)
After 2 105 PC-3, LNCaP, LNCaP-SF, or SaOS-2
cells and 1 105 BDSC-1, BDSC-2, or BmetSC cells were
plated onto six-well plates with RPMI 5% CCS or
DMEM 5% CCS, cells were treated with 0–300 mmol/L
tranilast for 48 hr. Culture medium was harvested and
centrifuged to remove debris. Samples were stored at
808C until use. TGF-b1 protein secretion was deter-
mined using Quantikine Human TGF-b1 (R&D Sys-
tems) according to the manufacturer’s instructions. In
each experiment, cells were harvested and cell number
was counted in triplicate using a hemocytometer.
The Prostate
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Values are expressed as secreted TGF-b1 pg/ml/
1 105 cells.
WoundAssay
The post-confluent LNCaP-SF cells were used in this
experiment. Wounds with a constant diameter were
made. Cells were treated with recombinant human
osteopontin (R&D Systems) alone or with tranilast in
5% CCS or serum free medium. The wound photo-
graphs were taken and the distance between the wound
edges was measured at 0 and 96 hr.
Patients
Sixteen patients with HRPC who had received
several salvage therapies that had not been effective
were orally administered tranilast at a dose of 300 mg/
day at Kanazawa University Hospital and associated
institutions. Before starting tranilast treatment, we
confirmed that PSA level continuously increased more
than three times despite one or more salvage therapies.
We did not start other new or alternative treatments.
However, in cases in which other treatments were
performed during tranilast treatment, this clinical
study was terminated. PSA was examined once in
a month. Stable disease was defined as the condition in
which PSA level was lower than that when tranilast
was started. All studies were performed after receiving
approval from the Institutional Review Board of
the Graduate School of Medical Science, Kanazawa
University, and after the subjects gave their informed
consent to participation in the study.
Statistical Analysis
Student’s t-test was used to determine the statistical
significance of differences in results of proliferation
assay, cellular area, and ELISA between the control and
others and differences in subcutaneous tumor size
between the control and treated groups in vivo. The
w2 test was used to determine the significance of
differences of radiographic changes between treated




Inoculated Into theDorsal Subcutis and theTibia
To explore the mechanism of the anti-tumor effect of
tranilast, we initially examined the direct effect of
tranilast on prostate cancer cell growth. Tranilast
diminished cell numbers of LNCaP, LNCaP-SF, and
PC-3 cells in a dose-dependent manner (Fig. 1A).
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Fig. 1. A:TranilastdecreasesproliferationofLNCaP,LNCaP-SF, andPC-3cells invitro.LNCaP,LNCaP-SF, andPC-3cellswere treatedwith
tranilast(0 ^300mmol/L)asdescribedinMaterialsandMethodsSection.After24hrofexposure,100mmol/Ltranilastcausedsignificantinhib-
ition in LNCaP-SF and PC-3 cells. After 72hr of exposure,30mmol/L tranilast caused significant inhibition in all cell lines (P< 0.05 ^ 0.001).
Points, mean ratio to control (n¼ 3); bars, SD.B: Four weeks after inoculation of LNCaP-SF cells, the dorsal tumor volume reached100 ^
200mm3, andmicewere divided into threegroups so thatmeanvolume of each groupbecome same.Themicewere then treated orally daily
for14 dayswithvehicle (control) or100 or 200mg/kg/dayof tranilast (*P¼ 0.048).Points,meanpercentof control (n¼ 6 per group); bars, SE.
C: Formice that received intratibial injection of LNCaP-SF cells, vehicle (control) or 300mg/kg/day of tranilast was administered orally for
14days from12weeks after injection.Micewere sacrificedat14weeks followingintratibial injection.Representativeradiographsof intact tibia
in the tranilast-treatedmiceandosteoblastic changesinvehicle-treatedcontrols are shown(n¼ 9pergroup).
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To confirm the effect of tranilast on tumor growth in
vivo, we inoculated LNCaP-SF into the dorsal subcutis
of SCID mice and treated mice with oral administration
of tranilast. Tranilast at 200 mg/kg/day significantly
reduced tumor volume to 50% of that in the control
group at 2 weeks after tranilast administration
(P¼ 0.048, Fig. 1B).
Next, as a model of osteoblastic metastasis, we used
LNCaP-SF cells for in vivo study because these cells
induced osteoblastic changes when inoculated into the
tibia of castrated male mice [20]. Vehicle and tranilast at
300 mg/kg/day were administered orally (n¼ 9 per
group). Radiographic evidence of osteoblastic lesions
was observed in eight of nine (88.9%) mice in the
control group. Whereas tranilast at 300 mg/kg/day
significantly inhibited osteoblastic changes in three of
nine (33.3%) mice (P¼ 0.016, Fig. 1C). No differences
were observed in body weight between the vehicle-
treated group and the tranilast-treated group (data not
shown).
Tranilast Induces Cell CycleArrest AssociatedWith
Induction ofp53, p21, andp27, andCausesApoptosis
Flow cytometric analysis revealed that tranilast
increased the distribution of cells remaining at G1
phase in LNCaP and LNCaP-SF cells in a dose-
dependent manner (Fig. 2A). Moreover, tranilast
increased the distribution of cells remaining at S phase
along with G1 phase increased in PC-3 cells in a dose-
dependent manner. Tranilast increased the levels of
p53, p21, and p27 mRNA and protein expression in
LNCaP and LNCaP-SF cells (Fig. 2B). In PC-3 cells,
which originally do not express p53, tranilast increased
the levels of p21 mRNA and protein expression but not
that of p27 mRNA. To further investigate whether the
anti-growth effect of tranilast is also associated with
apoptosis, we performed TUNEL assay. Nuclear
fragmentation, a typical morphological hallmark of
apoptosis, was observed following treatment with
300 mmol/L tranilast in LNCaP, LNCaP-SF, and PC-3
cells (Fig. 2C). Tranilast increased Fas and cleaved
product of PARP, and diminished full-length PARP in
LNCaP, LNCaP-SF, and PC-3 cells in a dose-dependent
manner (Fig. 2D).
Roles of SaOS-2 or Bone-Derived Stromal
Cells on LNCaP-SF
Since tranilast inhibited both tumor growth on the
dorsal subcutis of SCID mice osteoblastic changes
induced by LNCaP-SF in the tibia of SCID mice,
we explored for other potential mechanisms of the
inhibition of the osteoblastic changes caused by
tranilast, and focused on how tranilast affects TGF-b1
function.
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Fig. 2. Tranilast induces cell cycle arrest and apoptosis in LNCaP, LNCaP-SF, and PC-3 cells.A: Cell cycle analysis was performed with
flow cytometry as described inMaterials andMethods Section.Each panel shows representative results from one of the three experiments.
B:Westernblotting analyses ofcell-cycle-relatedgeneswereperformed.Twenty-fourhours aftereachprostate cancercell linewas seededat
1106 cells per 6-cm dish, tranilast was added (0 ^300mmol/L) for 48hr, and each cell line was harvested.C: Cells were treated with 0 or
300mmol/L tranilast for 48hr and TUNEL assay was performed.The existence of positively stained cells with nuclear fragmentation was
confirmedbyopticalmicroscopy.Arrowheadsindicateapoptoticcells.Bar,100mm.D:WesternblottinganalysisofFas(48kDa),full-lengthPARP
(112kDa), andproteolyticcleavageofPARP(85kDa),whichareapoptosis-relatedgenes.
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First, we established primary cultures of bone-
derived stromal cells, BDSC-1, BDSC-2, and BmetSC.
To confirm that BDSC-1, BDSC-2, and BmetSC were
stromal cells derived from bone tissue, we examined
the expression of the osteoblastic markers osteopontin
and cbfa-1 by RT-PCR [23]. Osteopontin mRNA
expression was observed in BDSC-1, -2, and BmetSC,
but not in PrSC, although cbfa-1 mRNA expression
was exhibited in all types of stromal cells examined
(data not shown). To seek evidence for the ability
of TGF-b1 production at the bone metastatic site to
induce proliferation of prostate cancer cells, we
cocultured SaOS-2 and BDSC, which produce high
levels of TGF-b1, with LNCaP-SF cells. As shown in
Figure 3A, coculture with SaOS-2 and BDSC strongly
induced proliferation of LNCaP-SF cells. These results
indicate that stromal cells can promote prostate
cancer proliferation at the osteoblastic metastatic site.
However, they do not prove that this occurs through
TGF-b1.
To determine if TGF-b1 produced by the stromal
cells could mediate the proliferative affect, we grew
prostate cancer cells and osteoblast-like cells in the
presence of TGF-b1. TGF-b1 did not induce any
changes in proliferation of LNCaP, LNCaP-SF, or PC-
3 cells (data not shown) indicating that the stromal cells




To determine if TGF-b1 impacted the osteoblastic
nature of the stromal cells in the osteoblastic metastatic
site, we cultured the stromal and SaOS-2 cells with
TGF-b1. Similar to the prostate cancer cell lines, TGF-b1
did not induce proliferation of SaOS-2, BDSC-1, BDSC-
2, and BmetSC (data not shown); however, it did induce
morphological transformation into polygonal cells and
marked increases in size (Fig. 3B, a–d). To express this
change as an objective value, we quantified the cellular
area in cultures treated with 0, 0.5, and 5 ng/ml of TGF-
b1 and 0.5 ng/ml of TGF-b1 with 10 mg/ml of pan-
specific TGF-b antibody using NIH image. TGF-b1
increased the cellular area by 6.2- and 5.6-fold as
compared with controls as in 0.5 and 5 ng/ml in BDSC-
1, 12.2- and 7.9-fold in BDSC-2, and 3.2- and 3.5-fold in
BmetSC. This effect was inhibited by addition of pan-
specific TGF-b1 antibody (Fig. 3B, left). To determine
whether TGF-b1 induced osteogenic differentiation of
BDSC, we examined the changes in osteopontin and
cbfa-1 mRNA levels by RT-PCR. The expression level of
osteopontin mRNA was increased by 0.5 and 5 ng/ml
of TGF-b1 and inhibited by pan-specific TGF-b1 anti-
body (Fig. 3B, right). These results indicated that TGF-
b1 promotes differentiation of BDSC at a low concen-
tration.
As TGF-b1 induced differentiation of BDSC, we
investigated if tranilast could impact this differentia-
tion. Morphological change induced by 0.5 ng/ml TGF-
b1 was inhibited in all BDSC by tranilast in a dose-
dependent manner (Fig. 3C, a–d). Tranilast decreased
the cellular area by 0.63- and 0.19-fold as compared
with 0 mmol/L at 100 and 300 mmol/L in BDSC-1, 0.49-
and 0.15-fold in BDSC-2, and 0.54- and 0.12-fold in
BmetSC (Fig. 3C, left). Furthermore, 100 mmol/L of
tranilast repressed the expression level of osteopontin
mRNA induced by 0.5 ng/ml TGF-b1 (Fig. 3C, right).
Tranilast InhibitsTGF-b1Production FromBone-
RelatedCells
To evaluate the effects of tranilast on TGF-b1
production from SaOS-2, BDSC-1, BDSC-2, and
BmetSC (bone-related cells), we measured secreted
TGF-b1 protein level in the culture medium on cells
treated with 0–300 mmol/L tranilast. Although PC-3
cells secreted TGF-b1 (<290 pg/ml at most), LNCaP
and LNCaP-SF cells hardly secreted TGF-b1. Tranilast
did not alter the secretion of TGF-b1 from these cell
lines. In contrast, bone-related cells secreted TGF-b1 in
the range of 600–1,100 pg/ml. Tranilast decreased
TGF-b1 secretion from these bone-related cells in a
dose-dependent manner. Especially, tranilast caused
significant inhibition at concentrations of 30 mmol/L
in BDSC-1 and BDSC-2, 100 mmol/L in SaOS-2, and
300 mmol/L in BmetSC (Fig. 4A).
Osteopontin PromotesMigration of LNCaPCells
To study the role of osteopontin in tumor migration,
we examined its ability to stimulate LNCaP-SF cell
migration in a wound assay (Fig. 4B). Because LNCaP-
SF cells formed osteoblastic lesion similar to typical
prostate cancer bone metastasis, we employed LNCaP-
SF cells for this experiment. Whereas LNCaP-SF cells in
5% CCS medium did not change migration rate even if
they were stimulated by osteopontin, LNCaP-SF cells
in serum-free medium with osteopontin had a signifi-
cantly higher migration rate compared with control.
The migration rate of LNCaP-SF was significantly




Our in vitro and murine model data suggested that
tranilast may have an impact on prostate cancer
growth. Accordingly, we performed a small clinical
evaluation of tranilast in patients with the goal of
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determining if tranilast would warrant a full clinical
trial. Table II lists baseline clinical characteristics of 16
patients with advanced HRPC. Six patients had both
bone metastases and lymph node metastases and eight
patients had bone metastases alone. Two patients had
local extra-prostate invasion ofT3 with no evidence of
metastasis. All patients had been treated with com-
bined androgen blockade (CAB) and followed by one
or more salvage therapies, nevertheless, their PSA
continued to increase at least three times before starting
tranilast. As shown in Figure 5, after commencement of
tranilast administration, PSA progression was inhib-
ited in four (25%) patients (for 13, 1, 10, and 3 months,
respectively). There were no differences in clinical
characteristics between cases in which tranilast was
and was not effective; however, all patients who
The Prostate
Fig. 3. Effects of TGF-b1and/or tranilast onbone-derived stromal cells.A: Coculture of LNCaP-SFwith SaOS-2 or bone-derived stromal
cellswasperformedas describedinMaterials andMethods Section.Bars, SD.B:Morphological transformations inBDSC-2 growing asrepre-
sentatives ofbone-derived stromal cellswere determinedbyphase-contrastmicroscopy.Bar, 200mm.Cellswere incubatedwithvarious con-
centrationsbetween0(control)(a),0.5(b),and5(c)ng/mlofTGF-b1and0.5ng/mlofTGF-b1with10mg/mlofpan-specificTGF-b antibody(d)daily
for10 days. As a sign of cellular differentiation, cellular areaswere gauged and quantifiedbyNIHimage to express the changeswith objective
values (left).To examine osteogenicdifferentiation,mRNAlevels ofosteopontin andcbfa-1were also examinedbyRT-PCR(right).C:Morpho-
logical transformations in BDSC-2 growing asrepresentatives ofbone-derived stromal cellswere determinedbyphase-contrastmicroscopy.
Cellswereincubatedwith0.5ng/mlofTGF-b1dailyandvaryingconcentrationsof tranilastbetween0(a),30(b),100(c),and300(d)mmol/Levery
otherday for10days.Cellularareasweregaugedandquantified(left),andmRNAlevelsofosteopontinandcbfa-1werealsoexaminedbyRT-PCR
(right) (*P< 0.05, **P< 0.01, ***P< 0.001).
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responded to tranilast had bone metastasis. Adverse
events were observed in two cases; elevation of liver
enzymes and headache in one case. Each adverse event
was improved rapidly after withdrawal of tranilast.
DISCUSSION
Tranilast, which is used as oral medicine for the
treatment of allergic diseases in Japan, showed an
inhibitory effect on proliferation of prostate cancer cells
both in vitro and in vivo. Moreover, our preliminary
clinical trial suggested that tranilast may be effective in
a subset of patients with HRPC without severe side
effects.
Flow cytometric analysis indicated that tranilast
arrested the cell cycle of LNCaP and LNCaP-SF cells in
the G1 phase. Cyclin-dependent kinases (CDKs) play a
central role in the cell cycle of mammalian cells and
promote G1/S transition by phosphorylation of the
retinoblastoma protein [24]. Intrinsic CDK inhibitors,
such as p21 and p27, bind to the CDK–cyclin complex
and inhibit its kinase activity, and p53 is a well-known
cellular transcription factor that stimulates the expres-
sion of various genes, including p21 [24,25]. We
clarified that tranilast up-regulated the levels of p53,
p21, and p27 expression in LNCaP and LNCaP-SF in a
dose-dependent manner. It was reported that tranilast
induced expression of p21 and p53 as well as G1 arrest,
and decreased CDK2 activity in uterine leiomyoma
cells and human malignant glioma cells [16,26].
Consistent with these reports, our results suggested
that tranilast induced G1 arrest in LNCaP and LNCaP-
SF cells via induction of p53, p21, and p27. On the other
hand, PC-3 cells, which have a mutation in p53 [27], did
not show changes in p27 expression and increased p21
expression, and accumulated in not only G1 phase but
also S phase. S phase checkpoints play critical roles in
maintaining genomic integrity and correct replication
of the genomic DNA. It was reported that apoptosis is
regulated through an S phase checkpoint controlled
by the checkpoint kinase (Chk)1-Cdc25A and Chk2-
Cdc25A pathways in C4-2 human prostate cancer cell
line which is androgen-independent and express low
levels of p53 [28]. Effects of tranilast on the cell cycle in
PC-3 cells may be different from those in LNCaP and
LNCaP-SF cells.
Moreover, apoptosis induced by tranilast was
confirmed based on the nuclear morphological
changes determined by TUNEL assay, and the levels
of expression of the apoptosis-related proteins Fas
and cleaved PARP were increased by tranilast. Up-
regulation of Fas occurs in tumor cells following
The Prostate
Fig. 4. A:ThechangesinTGF-b1secretioninprostatecancercelllines,SaOS-2,andbone-derivedstromalcellsby tranilastwereexaminedby
ELISA as described inMaterials andMethods Section.Bars, SD.B: Osteopontin (1mg/ml)was addeddaily and 300mmol/L tranilastwas added
everyotherdaytoLNCaP-SFcells.Woundphotographsweretakenunderphase-contrastmicroscopyatinitialtime(0hr)andtheterminationof
theexperiments (96hr).C:Resultsarepresentedas thepercentage to controlin5%CCS(*P< 0.05, **P< 0.01, ***P< 0.001).
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chemotherapy and may play a key role in evasion of
immune surveillance by eliminating infiltrating lym-
phocytes [29]. Thus, tranilast directly inhibits prostate
cancer cell proliferation by inducing cell cycle arrest
and apoptosis.
In the present study, the anti-tumor effect of tranilast
on LNCaP-SF xenografts was observed not only in
those injected subcutaneously but also in those with
direct tibial injection of castrated male SCID mice. The
extracellular bone matrix proteins of osteoblastic
lesions are known to enhance proliferation and differ-
entiation of prostate cancer cells in vivo and do so in
many culture systems. It was reported that osteoblast-
conditioned medium increased the proliferation and
expression of PSA at both the protein and mRNA levels
in LNCaP cells [30]. In addition, bone fibroblasts
differentially modulated LNCaP growth through the
release of paracrine-mediated growth factors [31]. We
also found that coculture of LNCaP-SF cells with bone-
related cells induced proliferation of LNCaP-SF cells.
Moreover, bone-related cells secreted higher levels of
TGF-b1 than prostate cancer cells, which tranilast
targets. However, our results showing that TGF-b1
did not directly stimulate prostate cancer cell growth
suggest that tranilast does not achieve its affects
through blocking a proliferative effect induced by
TGF-b1 on prostate cancer cells.
Among the cytokines in osteoblastic metastasis,
TGF-b requires activation from its precursor form,
which can be catalyzed by PSA, and plays an important
role in skeletal remodeling [32]. Kassem et al. [33]
reported that TGF-b1 increased osteoblastic cell pro-
liferation irrespective of their differentiation state.
Osteopontin, one of the most prevalent non-collage-
nous proteins secreted by osteoblasts accumulates in
the mineralized extracellular matrix and is involved in
bone remodeling and signaling [34]. Frank et al. [35]
also reported that the level of osteopontin mRNA can
be used as a marker to monitor the extent of bone
stromal cell osteogenic differentiation in vitro. Osteo-
pontin has also been implicated tumor invasion and
metastasis in prostate and other cancers. In the present
study, even a low concentration of TGF-b1 (0.5 ng/ml)
led BDSC to morphological transformation, increases
in size, and up-regulation of osteopontin mRNA. In
addition, osteopontin promoted LNCaP-SF cell migra-
tion. Taken together, these results suggested that TGF-
b1 may accelerate differentiation and its effects in cells
of the osteoblast lineage in an autocrine manner and
that tumor–stromal cell interaction plays an important
role in prostate cancer growth and progression in bone.
Platten et al. [26] and Yashiro et al. [36] also reported
that tranilast inhibited the release of TGF-b1 and -b2
from human malignant glioma cells and from gastric
fibroblasts. In the present study, we showed that
tranilast diminished TGF-b1 secretion from bone-
related cells in a dose-dependent manner, but not from
LNCaP, LNCaP-SF, or PC-3. Moreover, the differ-
entiation effects of TGF-b1 on BDSC were also inhibited
by tranilast in a dose-dependent manner. Tranilast may
not only directly inhibit the proliferation of prostate
cancer cells but also indirectly suppress TGF-b1-
associated osteoblast differentiation and proliferation,
and prostate cancer proliferation and migration via
inhibiting TGF-b1 and osteopontin secretion from
osteoblasts and stromal cells (Fig. 6).
The clinical study in this article is the first pilot trial
of tranilast use for treatment of patients with cancer.
PSA is a very sensitive, specific, and meaningful serum
marker for tumors of prostate origin in all clinical
situations and is correlated to clinical condition [37].
Generally, once prostate cancer becomes advanced
HRPC after several rounds of salvage therapy, the
general condition of the patient becomes worse with
continuous PSA progression without temporary recov-
ery. Our data showed that 4 of 16 patients with
advanced HRPC responded to oral 300 mg/day trani-
last administration with respect to PSA. Clinically,
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TABLE II. Characteristics of 16 Patients With Advanced
HRPC
Median age at diagnosis (range) 66.5 (57–88)
Median PSA ng/mL at diagnosis
(range)
200 (4.8–4,370)
Median PSA ng/ml at starting
tranilast (range)
25.8 (0.99–2,079)
Median months from diagnosis
to starting tranilast (range)
42 (12–89)









No. of lymph nodes 6










Castration included one case of surgical castration, while the
others were medical castrations.
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tranilast functioned as a cytostatic rather than a
cytotoxic agent. It was reported that the attainable
serum concentration of tranilast reaches 30–300 mmol/
L in vivo after oral administration of 600 mg/day
tranilast [38]. The administered dose of tranilast may be
too low to overcome multiple metastases. The results of
the present study, however, suggested that tranilast
may have beneficial effects on the inhibition of PSA
progression in a subset of patients with HRPC.
Although severe adverse events that result in discon-
tinuation of treatment can often occur in chemotherapy
and molecular targeting therapy, only two patients in
the present study had minor adverse events.
In addition, it was reported that tranilast inhibited
the IGF-1-induced cell growth in MCF-1 breast cancer
cells by blocking calcium entry [17]. IGF-1 is also
abundant in bone cortex and it was reported that IGF-1
plays a role as a risk factor in prostate cancer [39].
The Prostate
Fig. 5. Casesinwhichtranilast treatmentwaseffective.A:An80-year-oldpatientwhohadreceivedCAB,alternativeanti-androgens,EMP,
DEX, tegafur uracil, and incadronate as previous treatmentsmaintained stable disease for13months.This patientdied fromprostate cancer
19months after starting tranilast.B: A79-year-oldpatient treatedpreviouslywithCABandalternativeanti-androgensmaintainedstabledis-
ease for only1month, but PSA decreasedmarkedly after starting tranilast.C: A 57-year-old patient treatedpreviously with CAB, EMP, and
ethinylestradiolmaintained stable disease for10months.D: An 80-year-oldpatient treatedpreviously withCAB, alternative anti-androgens,
EMP, andDEXmaintained stable disease for 3months.Thispatient’s diseasewas still stable at the time of submissionof this study.Parts of the
clinicaldata of thesepatients arenot shownbecause theduration fromdiagnosis to starting tranilastwasverylongineachcase: 89, 28, 33, and
88months, respectively.
Fig. 6. Schematic illustration of the effects of TGF-b1and trani-
last. In site of bone metastases, osteoblasts and stromal cells
initially secretedTGF-b1,whichinducesproliferationandself-differ-
entiation, and subsequently they inducemigration andproliferation
of prostate cancer cells by releasing growth factors (GFs) or cyto-
kines(CKs)suchasosteopontininachainreaction.Tranilastdirectly
inhibits prostate cancer cell proliferation via cell cycle arrest and
induction of apoptosis. Tranilast also inhibits secretion of TGF-b1
from osteoblasts and stromal cells.Moreover, tranilast suppresses
the effects of TGF-b1 on stromal cells. Accordingly, osteoblastic
changesinbonemetastatic siteareinhibited.Althoughproliferation
withgrayrectanglementionedin schemawas notconfirmedin this
study; however, they were previously reported in some prostate
cancercell lines.
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Tranilast may inhibit proliferation of prostate caner in
bone metastasis meditated through suppression of
IGF-1 secretion from the bone cortex as well as TGF-b1.
Recently, Fan et al. [40] reported that tranilast may be
able to enhance the anti-tumor effect of romidepsin
(FK228, depsipeptide), a unique cyclic depsipeptide
with a histone deacetylase inhibitor activity, in
bladder cancer cells. Tranilast may also become a
useful chemical agent for combination therapy with
chemotherapy or molecular targeting therapy.
In conclusion, tranilast may be a useful new
therapeutic agent that can prolong survival and
improve the prognosis of HRPC patients. Tranilast
may be worth trying in HRPC patients before chemo-
therapy because it is administered orally and has few
side effects. Further studies are required to determine
the mechanism by which tranilast inhibits TGF-b1
production of bone stromal cells and TGF-b1 acts on
bone stromal cells and prostate cancer cells in bone
metastasis, and to specify the subpopulation for which
tranilast is effective. Moreover, as the study population
here was small and it was performed as an open-label
study with one arm, it is also necessary to assess larger
numbers of HRPC patients.
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W, Heberer M, Martin I. Real-time quantitative RT-PCR analysis
of human bone marrow stromal cells during osteogenic differ-
entiation in vitro. J Cell Biochem 2002;85:737–746.
36. Yashiro M, Murahashi K, Matsuoka T, Nakazawa K, Tanaka H,
Osaka H, Koyama T, Ohira M, Chung KH. Tranilast (N-3,4-
dimethoxycinamoyl anthranilic acid): A novel inhibitor of
invasion-stimulating interaction between gastric cancer cells
and orthotopic fibroblasts. Anticancer Res 2003;23:3899–
3904.
37. el-Shirbiny AM. Prostatic specific antigen. Adv Clin Chem 1994;
31:99–133.
38. Kusama H, Kikuchi S, Tazawa S, Katsuno K, Baba Y, Zhai YL,
Nikaido T, Fujii S. Tranilast inhibits the proliferation of human
coronary smooth muscle cell through the activation of p21waf1.
Atherosclerosis 1999;143:307–313.
39. Cheng I, Stram DO, Penny KL, Pike M, Le Marchand L, Kolonel
LN, Hirschhorn J, Altshuler D, Henderson BE, Freedman ML.
Common genetic variation in IGF1 and prostate cancer risk in the
multiethnic cohort. J Natl Cancer Inst 2006;18:123–134.
40. Fan J, Stanfield J, Guo Y, Karam JA, Frenkel E, Sun X, Hsieh JT.
Effect of trans-2,3-dimethoxycinnamoyl azide on enhancing
antitumor activity of romidepsin on human bladder cancer. Clin
Cancer Res 2008;15:1200–1207.
The Prostate
1234 Izumiet al.
